Barbara Troupin, MD, MBA
Belmont, California
Overview
I am a business-centric Biotech/Pharma/Life Science Executive and Board Advisor who scales for growth through clinical development, global regulatory strategy and medical/commercial positioning to maximize the probability of success. I am known for deep therapeutic area expertise with delivery of scientific and operational excellence, while fostering impactful relationships with all stakeholders. I maintain a comprehensive understanding of drug development and regulatory landscape from IND to NDA defense in the US and EU, resulting in multiple product approvals and US launches. As an insightfu
About
I am a business-centric Biotech/Pharma/Life Science Executive and Board Advisor who scales for growth through clinical development, global regulatory strategy and medical/commercial positioning to maximize the probability of success. I am known for deep therapeutic area expertise with delivery of scientific and operational excellence, while fostering impactful relationships with all stakeholders. I maintain a comprehensive understanding of drug development and regulatory landscape from IND to NDA defense in the US and EU, resulting in multiple product approvals and US launches. As an insightful member of the senior leadership team with extensive board experience, I guide companies in scaling for growth while asking the right questions for critical decisions. Notable achievements: • FDA APPROVALS: Obtained 20-2 vote as Lead Clinical Presenter at Qsymia FDA Advisory Committee, leading to FDA approval for VIVUS. Supported NDA filings for Stendra and Evamist, both resulting in approvals. • DEVELOPMENT STRATEGY: Builds comprehensive development programs addressing medical, scientific and market needs, regulatory requirements and strategic compound positioning to maximize value. Drives early Go-No Go decisions, halting studies/development when not supportive of compound success, and develops IP to protect innovation (holds two patents). • REGULATORY STRATEGY TRANSFORMATION: Revised Clinical Development Plans to achieve required regulatory elements addressing both safety and efficacy for successful FDA filing/approval – getting written FDA agreement and increasing regulatory probability of global clinical/regulatory success. • MEDICAL LEADERSHIP: Built medical affairs functionality from start to launch multiple times; evolving medical landscapes, building expert relationships, interacting at the highest level of scientific and medical rigor. • BOARD SERVICE: Independent Director at Equillium (Nasdaq:EQ). Active participation in Board meetings, joint Board/Management Committees and strategy sessions for MyoKardia (Nasdaq:MYOK), ERX (Private), Aquinox (Nasdaq: AQXP), Apricus (Nasdaq:APRI), and VIVUS (Nasdaq:VVUS). Coach and mentor - passionate about seeing individuals exceed expectations and achieve career/personal growth. Support has ranged from high school student through C-suite executives. Mentoring first generation college students, mid-career transitions, fractional roles and first Board seats.